Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
暂无分享,去创建一个
M. Cataldi | A. Colao | L. Annunziato | G. Lombardi | A. Colao | S. Cirillo | A. di Sarno | R. Pivonello | B. Merola | A. Sarno | M. L. Landi | F. Sarnacchiaro | G. Facciolli | S. Cirillo | G. Lombardi | Mauro Cataldi | Lucio Annunziato
[1] A. Colao,et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. , 1997, The Journal of clinical endocrinology and metabolism.
[2] M. Molitch,et al. Management of prolactinomas. , 1997, The Journal of clinical endocrinology and metabolism.
[3] M. Vance,et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. , 1996, Journal of Clinical Endocrinology and Metabolism.
[4] P. Marzullo,et al. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. , 1995, Hormone research.
[5] J. Webster,et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea , 1994, The New England journal of medicine.
[6] G. Sassolas,et al. Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. , 1994, Journal of pharmaceutical sciences.
[7] F. Flamigni,et al. Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study , 1992, Clinical endocrinology.
[8] F Pedersen,et al. Volume of Pituitary Macroadenomas: Assessment by MRI , 1992, Journal of computer assisted tomography.
[9] M. Scanlon,et al. Dopamine agonists and pituitary tumor shrinkage. , 1992, Endocrine reviews.
[10] G. Faglia. Should dopamine agonist treatment for prolactinomas be life‐long? , 1991, Clinical endocrinology.
[11] R. Roncucci,et al. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. , 1990, European journal of pharmacology.
[12] B. Claustrat,et al. Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas. , 1990, The Journal of clinical endocrinology and metabolism.
[13] I. Lancranjan,et al. RAPID AND LONG‐LASTING SUPPRESSION OF PROLACTIN SECRETION AND SHRINKAGE OF PROLACTINOMAS AFTER INJECTION OF LONG‐ACTING REPEATABLE FORM OF BROMOCRIPTINE (PARLODEL LAR) * , 1990, Clinical endocrinology.
[14] C. Miola,et al. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. , 1989, The Journal of clinical endocrinology and metabolism.
[15] R. Caldara,et al. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. , 1986, The Journal of clinical endocrinology and metabolism.
[16] M. Esiri,et al. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. , 1986, The Journal of clinical endocrinology and metabolism.
[17] A. Liuzzi,et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. , 1985, The New England journal of medicine.
[18] A. Grossman,et al. COMPARISON OF THE CLINICAL ACTIVITY OF MESULERGINE AND PERGOLIDE IN THE TREATMENT OF HYPERPROLACTINAEMIA , 1985, Clinical endocrinology.
[19] M. Vance,et al. Drugs Five Years Later: Bromocriptine , 1984 .